Materials and Methods for Pathologies in Muscle following Injury, Disease or Aging
AssigneeThe Brigham and Women S Hospital, Inc.
InventorRonald L. Neppl
Life of this patent
Estimating the term…
Abstract
Compositions comprising nuclear-localised Akt1 (Akt-NLS) fusion proteins, and methods of use thereof in cellular and animal models, and for treating muscle pathologies.
Claims24
An isolated engineered protein comprising an AKT serine/threonine kinase 1 (Akt1) linked to at least one nuclear localization sequence (NLS), optionally with a linker sequence therebetween.
A transgenic mouse, wherein one or more cells of the mouse comprise a sequence encoding an AKT serine/threonine kinase 1 (Akt1) linked to at least one nuclear localization sequence (NLS), optionally with a linker sequence therebetween, integrated in to the genome of the cell.
A method of reducing muscle fibrosis in a subject, the method comprising administering to muscle tissue of the subject a protein comprising an AKT serine/threonine kinase 1 (Akt1) linked to at least one nuclear localization sequence (NLS), optionally with a linker sequence therebetween.
A method of reducing muscle fibrosis in a subject, the method comprising administering a nucleic acid encoding a protein comprising an AKT serine/threonine kinase 1 (Akt1) linked to at least one nuclear localization sequence (NLS), optionally with a linker sequence therebetween, preferably wherein the nucleic acid comprises a promoter that directs expression specifically in striated muscle cells of the subject.
Dependencies are inferred from the claim text.